top of page

Hopewell Therapeutics’ CEO on the company’s $25M raise and next-gen LNPs

Lou Brenner discusses his company’s raise today and explains how Hopewell is designing LNPs to go beyond the liver.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page